Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-01-02-03 DPP4 inhibitors (gliptins)
| Sitagliptin |
|
Formulary
|
Tablets 25mg, 50mg, 100mg |
 MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis |
|
| Linagliptin Trajenta® |
|
Formulary
|
Tablets 5mg Second line gliptin on LSCMMG pathway for patients with renal impairment. |
|
MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis |
|
|
| Alogliptin Vipidia® |
|
Formulary
|
Tablets 6.25mg, 12.5mg, 25mg |
|
MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis |
|
|
Links
- FSRH Statement: Glucagon-like peptide-1 (GLP-1) agonists and oral contraception
- Diabetes UK: Diabetes when you’re unwell
LSCMMG: Diabetes - Choice of Safety Pen Needles and Lancets- LSCMMG: Diabetes - Pen Needles/Lancets
- LSCMMG: Diabetes - Position Statement Safety Needles and Safety Lancets
- LSCMMG: Diabetes Guideline for antihyperglycaemic therapy in adults with type 2 diabetes
- LSCMMG: Diabetes: Recommended meters, strips and devices
LSCMMG: GLP-1 patient contract- LSCMMG: Mounjaro® (Tirzepatide) for Type 2 Diabetes Position Statement
- LSCMMG: Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- MHRA Drug Safety Update April 2016: SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis
- MHRA Drug Safety Update April 2016: SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis
- MHRA Drug Safety Update April 2016: SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis
- MHRA Drug Safety Update December 2021: Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus
- MHRA Drug Safety Update Feb 2019: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum)
- MHRA Drug Safety Update Feb 2019: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum)
- MHRA Drug Safety Update Feb 2019: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum)
- MHRA Drug safety Update Feb 2019: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum)
- MHRA Drug Safety update June 2015: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
- MHRA Drug Safety Update June 2019: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA Drug Safety Update June 2019: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA Drug Safety Update June 2019: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA Drug SAfety Update June2019: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA Drug Safety Update March 2020: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA Drug Safety Update March 2020: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA Drug Safety Update March 2020: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA Drug Safety UpdateMarch 2020: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA website
- MHRA: Diabetes and driving
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation
- MHRA: GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse
- MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA: Insulin combined with pioglitazone: risk of cardiac failure
- MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products
- MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products
- MHRA: Pioglitazone: risk of bladder cancer
- MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
- MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
- MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
- MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
- National Patient Safety Alert
- NHSE guidance to primary care about unregulated providers who supply hormone medications to children and young people for gender incongruence
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE TA1075: Dapagliflozin for treating chronic kidney disease
- NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
- NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
- NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
- NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA875: Semaglutide for managing overweight and obesity
- NICE TA924: Tirzepatide for treating type 2 diabetes
- NICE TA942: Empagliflozin for treating chronic kidney disease
- Risk of acute pancreatitis. MHRA safety update Sept 12
- Rybelsus® (oral semaglutide): risk of medication error due to introduction of new formulation with increased bioavailability
- Serious hypersensitivity reactions & acute pancreatitis - Dear HCP Letter
- Tirzepatide: Mounjaro® (tirzepatide) for managing overweight and obesity in primary care